Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

HIV-to-HIV Transplant at MGH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02750397
Recruitment Status : Recruiting
First Posted : April 25, 2016
Last Update Posted : April 27, 2018
Sponsor:
Information provided by (Responsible Party):
David Wojciechowski, Massachusetts General Hospital

Brief Summary:
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. HIV+ individuals who receive a solid organ transplant from HIV-uninfected donors will also be followed.

Condition or disease
HIV Awaiting Organ Transplant

Detailed Description:

This is an observational study designed to evaluate safety and outcomes of solid organ transplantation in HIV+ recipients of HIV+ deceased donors. This study will evaluate overall survival and graft survival compared to transplantation with an HIV- organ.

In addition the study will assess potential complications of organ transplant using HIV+ deceased donors - including but not limited to - HIV superinfection, incidence and severity of graft rejection, recurrence of HIV-associated nephropathy, incidence of bacterial infections, and opportunistic infections.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
Study Start Date : August 2016
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort
HIV D+/R+
HIV+ recipients who receive an organ transplant from an HIV+ donor
HIV D-/R+
HIV+ recipients who receive an organ transplant from an HIV- donor



Primary Outcome Measures :
  1. Patient Survival [ Time Frame: One Year ]

Secondary Outcome Measures :
  1. Graft Survival [ Time Frame: One, Two, Three Years ]
  2. Graft Rejection [ Time Frame: One, Two, Three Years ]
  3. HIV Disease Progression [ Time Frame: One, Two, Three Years ]
  4. Development of antiretroviral resistance and X4 tropic virus [ Time Frame: Through study completion, up to three years ]
  5. Incidence of bacterial, fungal, viral and other opportunistic infections [ Time Frame: Through study completion, up to three years ]
  6. Incidence of other transplant complications (surgical and vascular) [ Time Frame: Through study completion, up to three years ]
  7. Analysis of recurrent HIV associated nephropathy [ Time Frame: Through study completion, up to three years ]
  8. Incidence of post-transplant malignancies [ Time Frame: Through study completion, up to three years ]
  9. Incidence of systemic HIV-superinfection [ Time Frame: Through study completion, up to three years ]
  10. Changes in HIV latent viral reservoir [ Time Frame: Through study completion, up to three years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All individuals with end-stage organ disease and HIV infection who meet standard clinical criteria for transplantation and the study inclusion and exclusion criteria will be eligible for participation in the study.
Criteria

Inclusion Criteria:

  1. Participant is able to understand and provide informed consent
  2. Participant meets standard listing criteria for transplant.
  3. Documented HIV infection (by any licensed ELISA and confirmation by Western Blot, positive HIV ab IFA, or documented history of detectable HIV-1 RNA).
  4. Participant is ≥ 18 years old.
  5. Opportunistic Complications: None or previous history of protocol allowed opportunistic infections or neoplasms with appropriate acute and maintenance therapy and no evidence of active disease.
  6. Participant CD4+ T-cell count is >/= 200/μL prior to renal transplant or for liver transplant is >/= 100/μL within 16 weeks prior to transplant and no history of opportunistic infection (OI); or ≥200 μL if history of OI is present.
  7. Participant HIV-1 RNA < 50 copies/mL (by any FDA-approved assay performed in CLIA-approved laboratory), in the 26 weeks prior to transplant. Non-consecutive viral "blips" between 50-400 copies RNA/mL will be allowed.
  8. Antiretroviral therapy: To avoid drug interactions, ritonavir or cobicistat-containing regimens are not recommended, unless in the opinion of the HIV/Transplant Infectious Disease team there is no alternative regimen expected to control HIV replication.
  9. Participant is willing to use PCP, herpes virus and fungal prophylaxis as indicated.

Exclusion Criteria:

  1. Participant has concomitant conditions that, in the judgment of the investigators, would preclude transplantation or immunosuppression.
  2. Opportunistic Complication History: Any history of progressive multifocal leukoencephalopathy (PML), chronic intestinal cryptosporidiosis of > 1 month duration, or primary CNS lymphoma.
  3. Participant has a history of any neoplasm except for the following: resolved kaposi's sarcoma, in situ anogenital carcinoma, adequatelytreated basal or squamous cell carcinoma of the skin, solid tumors (except primary CNS lymphoma) treated with curative therapy and disease free for more than 5 years. History of renal cell carcinoma requires disease free state for 2 years. History of leukemia and disease-free duration will be per site policy.
  4. Participant is pregnant or breastfeeding. Note: Participants who become pregnant post-transplant will continue to be followed in the study and will be managed per clinical practice. Women that become pregnant should not breastfeed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750397


Contacts
Layout table for location contacts
Contact: David Wojciechowski, DO dwojciechowski@mgh.harvard.edu
Contact: Margaret Thomas (617) 643-6266 mvthomas@mgh.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital

Layout table for additonal information
Responsible Party: David Wojciechowski, Director, Clinical Transplant Nephrology Research, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02750397     History of Changes
Other Study ID Numbers: The HOPE Act
First Posted: April 25, 2016    Key Record Dates
Last Update Posted: April 27, 2018
Last Verified: April 2018

Keywords provided by David Wojciechowski, Massachusetts General Hospital:
HIV
Kidney Transplant
Liver Transplant
Transplant